Key result
CABG and PTCA significantly improved quality of life dimensions like mobility (P<0.001 and P=0.004) at 8 years in CAD patients, whereas medication showed no significant changes.
Why the study?
Do CABG and PTCA improve long-term health-related quality of life compared to medication in patients with coronary artery disease?
Cohort (n=280)
Do CABG and PTCA improve long-term health-related quality of life compared to medication in patients with coronary artery disease?
CABG and PTCA provide sustained improvements in health-related quality of life up to 8 years post-intervention in patients with coronary artery disease, unlike medical therapy alone.
No takes yet. Share an insight, caveat, or question.
May support revascularization for sustained QoL in CAD; hypothesis-generating and requires randomized confirmation before practice change.
Lukkarinen et al. (2006) conducted a cohort in Coronary artery disease (n=280). CABG and PTCA vs. Medication was evaluated on Health-related quality of life (HRQoL) measured using the Nottingham Health Profile. CABG and PTCA significantly improved quality of life dimensions like mobility (P<0.001 and P=0.004) at 8 years in CAD patients, whereas medication showed no significant changes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: